Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
Christina TryfonosMaria ChrysafiKonstantinos VadikoliasLefteris BerberoglouTheofanis VorvolakosSophia DimolianiGerasimos TsourouflisChristos KontogiorgisGeorgios AntasourasConstantinos GiaginisPublished in: Journal of neurology (2024)
A good nutritional status appears to slow down disease progression and ameliorate symptoms' intensity in patients with multiple sclerosis (MS). Up to date, there are several interventional studies, which have explored the potential beneficial effects of specific dietary patterns as well as specific bioactive nutrients against disease progression and symptomatology of MS patients. This is a thorough, scoping review, which aims to critically summarize and scrutinize the currently available clinical evidence of the potential beneficial effects of nutritional interventional studies against MS progression and symptomatology. This review was conducted to systematically map the research done in this area, as well as to identify gaps in knowledge. For this purpose, we thoroughly explored the most accurate scientific web databases, e.g., PubMed, Scopus, Web of Science, and Google Scholar to achieve the most relevant clinical human studies applying effective and characteristic keywords. There are currently several dietary patterns and specific bioactive nutrients that show promising results by slowing down disease progression and by improving MS symptoms. However, there are also certain conflicting results, while most of the existing studies enrolled a small number of MS patients. Nutritional interventions may exert substantial protective effects against MS progression and symptomatology. However, large, long-term, randomized, double-blind, controlled clinical trials with a prospective design are strongly recommended to delineate whether such nutritional intervention may attenuate disease progression, and improve symptomatology in MS patients.
Keyphrases
- mass spectrometry
- end stage renal disease
- multiple sclerosis
- clinical trial
- ms ms
- ejection fraction
- chronic kidney disease
- newly diagnosed
- double blind
- healthcare
- randomized controlled trial
- prognostic factors
- endothelial cells
- case control
- peritoneal dialysis
- high resolution
- physical activity
- open label
- machine learning
- patient reported outcomes
- depressive symptoms
- study protocol
- phase iii
- artificial intelligence